Max Lataillade
Overview
Explore the profile of Max Lataillade including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
773
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang Y, Bush M, Yazdani P, Zhan J, Wen B, Bainbridge V, et al.
Pharmacol Res Perspect
. 2023 Nov;
11(6):e01151.
PMID: 37961928
GSK3640254 (GSK'254) is a novel HIV-1 maturation inhibitor with pharmacokinetics supporting once-daily (QD) therapy for HIV-1 treatment. This thorough QT/corrected QT (QTc) study evaluated the effect of GSK'254 on cardiac...
2.
Aberg J, Shepherd B, Wang M, Madruga J, Mendo Urbina F, Katlama C, et al.
Infect Dis Ther
. 2023 Sep;
12(9):2321-2335.
PMID: 37751019
Introduction: Efficacy and safety of the attachment inhibitor fostemsavir + optimized background therapy (OBT) were evaluated through 48 and 96 weeks in the phase 3 BRIGHTE trial in heavily treatment-experienced...
3.
Zhang Y, Joshi S, Yazdani P, Zhan J, Wen B, Bainbridge V, et al.
Br J Clin Pharmacol
. 2023 Aug;
90(1):274-285.
PMID: 37621050
Aims: This phase I study investigated potential drug-drug interactions of the maturation inhibitor GSK3640254 (GSK'254) with darunavir/ritonavir (DRV/RTV) and/or etravirine (ETR). Methods: In this randomized, open-label, single-sequence, multiple-dose study, healthy...
4.
Zhang Y, Johnson M, Joshi S, Yazdani P, Zhan J, Wen B, et al.
Br J Clin Pharmacol
. 2023 Feb;
89(7):2236-2245.
PMID: 36822839
Aims: GSK3640254 (GSK'254) is an HIV-1 maturation inhibitor with pharmacokinetics (PK) supporting once-daily dosing. GSK'254 will be co-administered with cytochrome P450 enzyme substrates and drug transporters, including other antiretrovirals, in...
5.
Krystal M, Chabria S, Austin D, Wolstenholme A, Wensel D, Lataillade M, et al.
Antivir Ther
. 2022 Oct;
27(5):13596535221131164.
PMID: 36191080
Background: The GSK3732394 multivalent protein was developed as a novel, long-acting, antiretroviral biologic treatment regimen with three independent, non-cross-resistant mechanisms for inhibiting HIV-1 entry. Methods: A single-centre, Phase 1, double-blind,...
6.
Gartland M, Cahn P, DeJesus E, Diaz R, Grossberg R, Kozal M, et al.
Antimicrob Agents Chemother
. 2022 May;
66(6):e0175121.
PMID: 35502922
In the phase 3 BRIGHTE study in heavily treatment-experienced adults with multidrug-resistant HIV-1, fostemsavir plus optimized background therapy (OBT) resulted in sustained rates of virologic suppression through 96 weeks. HIV-1...
7.
Spinner C, Felizarta F, Rizzardini G, Philibert P, Mitha E, Domingo P, et al.
Clin Infect Dis
. 2022 Jan;
75(5):786-794.
PMID: 34996113
Background: GSK3640254 (GSK'254) is a next-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor with pharmacokinetics (PK) supporting once-daily therapy. Methods: This phase IIa double-blind (sponsor-unblinded), randomized, placebo-controlled, adaptive study...
8.
Johnson M, Pene Dumitrescu T, Joshi S, Mathew A, Bainbridge V, Zhan J, et al.
Clin Pharmacol Drug Dev
. 2022 Jan;
11(5):632-639.
PMID: 34995417
GSK3640254 is a next-generation maturation inhibitor with demonstrated potency across HIV-1 subtypes and a high barrier to emergent resistance. This phase I, 2-part, randomized, open-label study (ClinicalTrials.gov identifier, NCT04263142) in...
9.
Rose R, Gartland M, Li Z, Zhou N, Cockett M, Beloor J, et al.
AIDS
. 2021 Oct;
36(1):11-18.
PMID: 34628442
Background: Temsavir (TMR), the active agent of the gp120-directed attachment inhibitor fostemsavir (FTR), the CD4-directed attachment inhibitor ibalizumab (IBA), and the CCR5 antagonist maraviroc (MVC) are antiretroviral agents that target...
10.
Pene Dumitrescu T, Greene T, Joshi S, Xu J, Johnson M, Halliday F, et al.
Br J Clin Pharmacol
. 2021 Aug;
88(4):1704-1712.
PMID: 34427938
Aims: GSK3640254 is a next-generation maturation inhibitor likely to be coadministered with combined oral contraceptives in HIV-positive women. Methods: This phase I, open-label, 1-way study assessed pharmacokinetic and pharmacodynamic interactions...